Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 112 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line... December 22, 2021 Can I Have a Nonviolent Relationship with Cancer? (Part 1) November 15, 2021 Medicare Open Enrollment is Almost Here-What You Need to Know for... October 13, 2020 No Survival Advantage from Radical Hysterectomy in Patients with Cervical Cancer... September 22, 2020 Load more HOT NEWS A Cancer Revolution comes to Manchester: Patrick’s review New ESMO Framework to Resolve Uncertainties About the De-intensification of Cancer... Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in... Surprise! Financial Assistance To Help With Your Medical Bills May Be...
